Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP; December 16-19), there were positive opinions for four investigational drugs issued on Friday.
Firstly, the CHMP has recommended granting a conditional marketing authorization for US health care giant Johnsons & Johnson (NYSE; JNJ subsidiary Janssen Cilag’s Sirturo (bedaquiline) for use as part of a combination therapy for pulmonary multidrug-resistant tuberculosis in adults when an effective treatment regime cannot otherwise be composed for reasons of resistance or tolerability. Sirturo has an orphan designation
Additional studies are required post authorization to further define the optimal use of this agent, both with regards the number and types of agents that are needed in combination, and the optimal treatment duration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze